Daneng Li, MD

Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.

Oncologists provide an overview of the treatment management of Child-Pugh B patients with advanced HCC.

In this discussion, panelists outline treatment considerations for patients with advanced HCC in the 2L setting and beyond.

In the context of frontline treatment strategies in advanced HCC, expert oncologists review clinical research in systemic immunotherapy approaches.

Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.

Oncologists review a patient profile, evaluating treatment approaches for patients with advanced HCC that have progressed beyond 1L treatment.

Experts discuss treatment options for patients unsuitable for atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.

Panelists share real-world evidence involving the use of lenvatinib in advanced HCC.

A panel of oncologists review a patient profile, evaluating a patient with advanced HCC treated with lenvatinib.

Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.

Experts discuss the factors they take into consideration when selecting the appropriate treatment in advanced HCC.

Panelists review the HIMALAYA study, investigating durvalumab plus tremelimumab in patients with advanced HCC.

Expert oncologists discuss a patient profile in advanced HCC, evaluating a patient treated with durvalumab plus tremelimumab.

Experts review clinical studies evaluating TACE in patients with intermediate stage HCC.

Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).

Drs Anthony B. El-Khoueiry, Daneng Li, Nicole Rich, and Pierre Gholam share treatment approaches for a 63-year-old woman who received an advanced HCC diagnosis with Child-Pugh A liver function.

Dr Nicole Rich discusses immunotherapy and potential combinations in intermediate and advanced hepatocellular carcinoma.

Key opinion leaders in gastrointestinal cancers provide insight on unmet needs and challenges in the treatment of advanced hepatocellular carcinoma in the second-line and beyond setting.

Experts in gastrointestinal cancers comment on their treatment approaches for patients with second-line advanced hepatocellular carcinoma who receive frontline TKI therapy.

Experts in gastrointestinal cancers share factors to consider when selecting the optimal second-line therapy for patients with advanced hepatocellular carcinoma.

Pierre Gholam, MD, comments on systemic immunotherapy options for second-line and beyond treatment of advanced hepatocellular carcinoma.

Anthony B. El-Khoueiry, MD, reviews anti-angiogenic systemic therapy options for patients with advanced HCC in the second-line and beyond setting.

An expert gastroenterologist, Dr Pierre Gholam, discusses the phase 3 LAUNCH trial and shares insight on the potential role of liver-directed therapy in the treatment of advanced hepatocellular carcinoma.

Daneng Li, MD, discusses novel regimens in the pipeline being evaluated for the treatment of frontline advanced HCC.

Experts in gastrointestinal cancers, Drs Pierre Gholam and Daneng Li, comment on the role of single-agent immunotherapy for first-line treatment of advanced HCC.

Pierre Gholam, MD, considers the optimal treatment selection for patients in whom an atezolizumab-bevacizumab combination isn’t a suitable frontline therapeutic option.

Nicole Rich, MD, reviews the patient selection for atezolizumab-bevacizumab and discusses patients in whom this regimen is contraindicated in the frontline setting in advanced HCC.

Dr Daneng Li reviews updated safety and efficacy results of durvalumab plus tremelimumab from the phase 3 HIMALAYA study in frontline unresectable HCC.

Daneng Li, MD, evaluates the use of cabozantinib plus atezolizumab in first-line advanced unresectable HCC as seen in the COSMIC-312 study.

Anthony B. El-Khoueiry, MD, provides insight on the evolution of care for frontline systemic therapy in advanced HCC and discusses currently approved first-line standard of care options.